In recent years, inhibitors targeting the PI3K-Akt signaling pathway rapidly became under focus for clinical investigation in anti-cancer therapy, and encouraging evidence indicates the potential of PI3K-Akt drugs in both hematological malignancies as well as solid tumors [26,27,28]. Here, AKT1 is linked to cancer.